Rachel Sachs is a scholar of innovation policy whose work explores the interaction of intellectual property law, food and drug regulation, and health law. Her work examines problems of innovation and access, considering how law helps or hinders these problems.
Yesterday, it was announced that Allergan had transferred the ownership of the patents on its billion-dollar drug Restasis, used for the treatment of chronic dry eye, to the Saint Regis Mohawk Tribe. The Tribe then exclusively licensed the drug back to Allergan, in exchange for tens of millions of dollars in both licensing and royalty fees. Although it may not sound like it, this transfer is potentially huge news in the drug pricing world. It is also extremely complex, and its full implications have yet to be determined.
The 21st Century Cures Act and key changes made during its drafting remain controversial and show the need for a more informed comment period for future health care legislation, says an expert on health law at Washington University in St. Louis.
Despite announcing in his first press conference that he would deal with a pharmaceutical industry “getting away with murder,” President-elect Donald Trump doesn’t seem to have a clear path for how he will reduce drug prices, said Rachel Sachs, associate professor of law and expert on drug regulation and health law.
The 21st Century Cures Act, the vast bill aimed at bolstering medical research and revamping the way drugs are approved, is a step in the right direction but is far from perfect, says an expert on the health care industry at the School of Law at Washington University in St. Louis.
Recent scandals involving high-priced generic drugs should prompt us to consider price controls for pharmaceutical companies, says an expert on the health care industry at the School of Law at Washington University.